Hoth Therapeutics Reports Positive CLEER-001 Clinical Trial Results.

Hoth Therapeutics announced positive interim results from its CLEER-001 clinical trial evaluating HT-001 in cancer patients receiving EGFR inhibitor therapy. The primary endpoint, ARIGA, improved by ~50% from baseline by Week 6, with all evaluable patients reaching low-severity disease. Additional endpoints showed a ~34% improvement in oncology toxicity and a ~37% reduction in patient-reported pruritus.